Mirdametinib Approval Brings Tumor Shrinkage and QOL Advantages to NF1-PN
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Staying on mirdametinib (Gomekli) for as long as possible may offer benefits related to tumor shrinkage and quality of life (QOL) for pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN), according to Christopher L. Moertel, MD.
Moertel, a professor in the Department of Pediatrics, director of the Pediatric Neuro-Oncology Fellowship Program in the Division of Pediatric Hematology/Oncology, and medical director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota, spoke with CancerNetwork® ahead of the FDA approval of mirdametinib in NF1-PNs about how this regulatory decision may impact the treatment field.1
On top of the agent’s advantages associated with QOL and tumor responses, Moertel highlighted the dispersible tablet formulation of mirdametinib as an important aspect of treatment. He indicated that the agent’s formulation may be useful in the treatment of patients who have difficulty swallowing pills or similar oral medication.
Findings from the phase 2b ReNeu trial (NCT03962543), which supported the FDA’s approval of mirdametinib in NF1-PNs, showed clinically relevant objective responses in adult (P <.001) and pediatric patients (P <.001) patients who received mirdametinib.2 In the adult and pediatric cohorts, respectively, treatment had significant impacts on patient-reported outcomes such as worst tumor pain severity (P <.001; P = .003).
Transcript:
This [approval] would open a new route to FDA-approved, on-label therapy for adults [and children] with NF1-associated plexiform neurofibroma. That’s very important. In addition, mirdametinib is available as a dispersible tablet, so for our patients who have difficulty swallowing pills, that preparation is extremely important. The schedule that was indicated for this trial and will likely be on the indication is 3-weeks-on, [then] 1-week-off.
We’re doing a lot in this trial to help patients stay on the medicine for a long period of time. We believe that staying on as long as possible benefits them as far as QOL and objectively shrinking their tumors. All of those things are advantages for this drug that we’ve been looking forward to.
References
- FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. News release. FDA. February 11, 2025. Accessed February 11, 2025. https://tinyurl.com/ymr3ft29
- Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. Published online November 8, 2024. doi:10.1200/JCO.24.01034
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Toxicity After Chemo May be Avoided With Anastrozole Combo in Breast Cancer
December 25th 2023It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.
